THRD (Third Harmonic Bio Inc.) Net Profit

THRD (Third Harmonic Bio, Inc.) - company brandmark

The profit generated by Third Harmonic Bio (THRD) on the chart correlates with expectations for KIT inhibitor trials and the potential of allergy therapies. The value of -0.05 represents the current metric level. Protected patents and a complete absence of debt form the business foundation. Efficiency is driven by a virtual management structure, where top management loyalty is secured through significant equity stakes, eliminating mass hiring costs.

THRD (Third Harmonic Bio) Net Profit history from 04/28/2023 to 08/16/2025

Analytical breakdowns and data insights for company Third Harmonic Bio, Inc. (THRD)

- price and consensus price forecast:
Stock Quotes Third Harmonic Bio Inc|THRD - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Third Harmonic Bio Inc|THRD - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Third Harmonic Bio|THRD - Book Capitalization|Market Capitalization to Book Value thirdharmonicbio.com|THRD - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Third Harmonic Bio|THRD - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Third Harmonic Bio Inc.|THRD - Company Total Debt|Debts to Book Capitalization Third Harmonic Bio Inc|THRD - Company Long-Term Debt|Company Short-Term Indebtedness Third Harmonic Bio|Immediate Liquidity thirdharmonicbio.com
- net income and valuation multiples indicators:
THRD - Net Income
Summary company analysis:Third Harmonic Bio
Core merchandise of Third Harmonic Bio, Inc

Investors must evaluate the asset's fundamental stability by analyzing operating profit, which measures real business efficiency stripped of subjective assessments and market noise. The bottom-line profit trend for Third Harmonic Bio (THRD) on the GURU.Markets platform reflects the impact of AI-driven compound selection automation, which reduces manual labor costs and directly determines the profitability trajectory of Third Harmonic Bio.

Main competitors

Net Income argenx BVBA|BNTX (BioNTech SE) - Net Profit|Net Profit Abivax Pharma|Net Income ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Final Profit|Net Profit IMVT (Immunovant Corp)|Net Financial Result Kiniksa Corp (KNSA)|GRFS - Company Net Income|adaptivebiotech.com (ADPT) - Net Income|Celldex Therapeutics, Inc. (CLDX) - Company Net Income|Net Income Aurinia Pharmaceuticals Inc|Net Income BCRX|Net Profit Vera Corp|Company Net Income Dianthus Therapeutics (DNTH)|pharvaris.com - Company Profit|Net Profit ABCL (AbCellera Biologics Inc)|Tourmaline Bio Inc (TRML) - Company Net Income|PGEN: Net Income|Pharming Corp - Profit After Payment of Taxes|NKTR: Net Profit|upstreambio.com - Final Profit|ZBIO (Zenas Biopharma) - Net Profit|Immunome Inc (IMNM) - Net Financial Result|Company Net Income Gossamer Corp (GOSS)|KALV (KalVista Corp) - Final Profit|Net Profit SEPN (Septerna Inc)|PVLA: Company Profit|SVRA: Net Income|Final Profit RIGL (Rigel Pharma)|ANAB: Net Profit|Astria Corp - Final Profit|ENGN (enGene Holdings Inc.) - Net Profit|Net Profit rapt.com|Company Net Income Aerovate Therapeutics Inc (JBIO)|ACRS (Aclaris Therapeutics Inc.) - Final Profit|Company Net Income Kyverna KYTX|TLSA - Net Income|CABA - Company Net Income|Company Net Income ventyxbio.com|Theratechnologies (THTX) - Company Net Income|Company Profit AVTX|ELDN (Eledon) - Net Profit|Agenus, Inc (AGEN) - Net Financial Result|Net Profit CLYM|Net Income zurabio.com ZURA|aTyr Pharma - Net Income|Final Profit ADAG|Ikena Oncology, Inc. - Net Profit|STTK: Company Net Income|EQ: Net Profit|CNTB - Net Financial Result|Company Net Income Immunic Therapeutics|Company Net Income Atara Biotherapeutics Inc ATRA|Net Income IFRX (InflaRx N.V.)|Profit After Payment of Taxes XFOR|Net Profit ACET (Adicet Bio, Inc.)|Final Profit CELU|INMB - Company Net Income|Final Profit BRNS (Barinthus Biotherapeutics PLC)|KZR: Net Profit|Company Profit SABS|Company Net Income Akari Therapeutics|Enlivex Therapeutics, Ltd. - Profit After Tax|Net Profit QTTB|GOVX (GeoVax Labs) - Final Profit|Net Profit EDSA (Edesa)|Net Profit iBio Corporation IBIO|CARM - Company Net Income|Final Profit XTLB (xtlbio.com)|boltbio.com (BOLT) - Company Net Income|Net Income HCW Biologics|APVO (Aptevo Therapeutics, Inc.) - Net Profit|Net Profit aimimmuno.com|Net Income ADTX (Aditxt)|GRI (gribio.com) - Final Profit|Net Profit XRTX (XORTX Therapeutics)|Net Financial Result Vyome Holdings Inc. (HIND)|REVB - Company Net Income|Indaptus Corp (INDP) - Net Income|Scinai Immunotherapeutics (SCNI) - Company Net Income|Net Income CalciMedica|Net Income AFMD|Net Profit Allakos Therapeutics|Company Net Income HOOKIPA Pharma Inc. (HOOK)|igmbio.com - Company Profit|Net Profit ITOS (iTeos Therapeutics)|oceanbiomedical.com (OCEA) - Company Net Income|TCBP: Net Income